Market Overview

UPDATE: Stifel Nicolaus Initiates Becton, Dickinson and Company at Hold; Acceleration Postponed

Share:
Related BDX
Earnings Scheduled For May 5, 2016
UPDATE: BD Announces Divestment of Vertebral Augmentation Solutions Business to Stryker; Terms Not Disclosed
My Portfolio Update: I Have 83 Stocks Now - 9 New Including 3 Defensive Picks With Selling 4 (Seeking Alpha)

Stifel Nicolaus initiated coverage on Becton, Dickinson and Company (NYSE: BDX) with a Hold rating.

Stifel Nicolaus noted, "BD is a premier hospital supplies and diagnostic company with leading market shares in most of its major segments. Sales growth appears to have stabilized now in the ~4%-5% range ex-FX for two consecutive quarters -- following a sharp deceleration in the FY2009-2011 timeframe. But headwinds remain, given the ongoing difficulties of redicting improving global healthcare spending trends. As well, the lack of major visible new growth drivers, increased Diagnostic Systems division competition, and ongoing uncertainties surrounding government funding for the Biosciences division remain challenging."

Becton, Dickinson and Company closed at $75.59 on Monday.

Latest Ratings for BDX

DateFirmActionFromTo
Feb 2016Deutsche BankUpgradesHoldBuy
Feb 2016CitigroupMaintainsNeutral
Jan 2016Evercore ISI GroupDowngradesBuyHold

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (BDX)

View Comments and Join the Discussion!